JP2023548295A5 - - Google Patents
Info
- Publication number
- JP2023548295A5 JP2023548295A5 JP2023525517A JP2023525517A JP2023548295A5 JP 2023548295 A5 JP2023548295 A5 JP 2023548295A5 JP 2023525517 A JP2023525517 A JP 2023525517A JP 2023525517 A JP2023525517 A JP 2023525517A JP 2023548295 A5 JP2023548295 A5 JP 2023548295A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- salt
- formula
- absent
- linking group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063110837P | 2020-11-06 | 2020-11-06 | |
| US63/110,837 | 2020-11-06 | ||
| PCT/US2021/058232 WO2022098990A1 (en) | 2020-11-06 | 2021-11-05 | Targeted conjugates comprising modified sirna |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023548295A JP2023548295A (ja) | 2023-11-16 |
| JP2023548295A5 true JP2023548295A5 (enExample) | 2024-11-13 |
Family
ID=81457390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023525517A Pending JP2023548295A (ja) | 2020-11-06 | 2021-11-05 | 修飾されたｓｉＲＮＡを含む標的化コンジュゲート |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240052349A1 (enExample) |
| EP (1) | EP4240369A4 (enExample) |
| JP (1) | JP2023548295A (enExample) |
| KR (1) | KR20230104652A (enExample) |
| CN (1) | CN116472063A (enExample) |
| AU (1) | AU2021376390A1 (enExample) |
| CA (1) | CA3199757A1 (enExample) |
| IL (1) | IL302530A (enExample) |
| MX (1) | MX2023005138A (enExample) |
| TW (1) | TW202233243A (enExample) |
| WO (1) | WO2022098990A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI859114B (zh) * | 2016-04-11 | 2024-10-21 | 加拿大商艾爾布圖斯生技公司 | 靶向組合物 |
| TWI866590B (zh) * | 2022-11-08 | 2024-12-11 | 大陸商南京明德新藥研發有限公司 | 含七元雜環的四價綴合基團及其應用 |
| WO2026061476A1 (zh) * | 2024-09-19 | 2026-03-26 | 长春金赛药业有限责任公司 | 一种多簇连接子、其制备方法及应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050222064A1 (en) * | 2002-02-20 | 2005-10-06 | Sirna Therapeutics, Inc. | Polycationic compositions for cellular delivery of polynucleotides |
| US20130190383A1 (en) * | 2010-04-26 | 2013-07-25 | Marina Biotech, Inc. | Nucleic acid compounds with conformationally restricted monomers and uses thereof |
| JP6924744B2 (ja) * | 2015-07-17 | 2021-08-25 | アークトゥラス・セラピューティクス・インコーポレイテッドＡｒｃｔｕｒｕｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | Ｂ型肝炎ウイルスに対する組成物および薬剤ならびにその使用 |
| TWI859114B (zh) * | 2016-04-11 | 2024-10-21 | 加拿大商艾爾布圖斯生技公司 | 靶向組合物 |
| CA3059426A1 (en) * | 2017-04-11 | 2018-10-18 | Arbutus Biopharma Corporation | Targeted compositions |
| US11324820B2 (en) * | 2017-04-18 | 2022-05-10 | Alnylam Pharmaceuticals, Inc. | Methods for the treatment of subjects having a hepatitis b virus (HBV) infection |
| CN111212909A (zh) * | 2017-10-17 | 2020-05-29 | 箭头药业股份有限公司 | 用于抑制去唾液酸糖蛋白受体1的表达的RNAi试剂和组合物 |
| MA55375A (fr) * | 2019-03-20 | 2022-01-26 | Arbutus Biopharma Corp | Méthodes thérapeutiques de traitement de l'hépatite b |
-
2021
- 2021-11-05 CN CN202180078408.9A patent/CN116472063A/zh active Pending
- 2021-11-05 US US18/035,695 patent/US20240052349A1/en active Pending
- 2021-11-05 WO PCT/US2021/058232 patent/WO2022098990A1/en not_active Ceased
- 2021-11-05 EP EP21890140.3A patent/EP4240369A4/en active Pending
- 2021-11-05 JP JP2023525517A patent/JP2023548295A/ja active Pending
- 2021-11-05 MX MX2023005138A patent/MX2023005138A/es unknown
- 2021-11-05 KR KR1020237018346A patent/KR20230104652A/ko active Pending
- 2021-11-05 AU AU2021376390A patent/AU2021376390A1/en active Pending
- 2021-11-05 CA CA3199757A patent/CA3199757A1/en active Pending
- 2021-11-05 IL IL302530A patent/IL302530A/en unknown
- 2021-11-08 TW TW110141540A patent/TW202233243A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100400045C (zh) | 基于核酸的化合物及其使用方法 | |
| JP2026062680A (ja) | 核酸のデリバリーのための新規脂質および脂質ナノ粒子製剤 | |
| IL301757A (en) | Cystic fibrosis transmembrane regulator conductance modulators | |
| JP2023536320A5 (enExample) | ||
| JP2011500758A5 (enExample) | ||
| JP2006502143A5 (enExample) | ||
| JP2007529421A5 (enExample) | ||
| JP2014515406A5 (enExample) | ||
| JP2015501833A5 (enExample) | ||
| JP2012523415A5 (enExample) | ||
| JP2018520685A5 (enExample) | ||
| JP2012158602A5 (enExample) | ||
| JP2006507265A5 (enExample) | ||
| JP2004537517A5 (enExample) | ||
| JP2018520685A (ja) | Ｂ型肝炎ウイルスに対する組成物および薬剤ならびにその使用 | |
| JP2007520452A5 (enExample) | ||
| JP2023509870A5 (enExample) | ||
| JP2023505434A5 (enExample) | ||
| JP2011509302A5 (enExample) | ||
| JP2008506710A5 (enExample) | ||
| CN114409554A (zh) | 一种新型阳离子脂质化合物及其组合物和用途 | |
| JP2025500860A5 (enExample) | ||
| JP2022544538A5 (enExample) | ||
| JP2005517677A5 (enExample) | ||
| JP2018532786A5 (enExample) |